AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 923067 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocainide (400 to 1100 mg every 12 hours during cross-over)
Number of subjects: 12
Study 923067 — intervention group
Group type: COMPARATOR
Intervention: Placebo (during cross-over)
Number of subjects: 12
Study 29315019 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily almond intake (56 g per day for 20 weeks)
Number of subjects: 0
Study 29315019 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric control food
Number of subjects: 0
Study 26237936 — intervention group
Group type: EXPERIMENTAL
Intervention: Soladey-3 titanium dioxide semiconductor toothbrush
Number of subjects: 71
Study 26237936 — intervention group
Group type: COMPARATOR
Intervention: Inactive control device (toothbrush with inert resin core)
Number of subjects: 71
Study 26237936 — intervention group
Group type: COMPARATOR
Intervention: Both active and control treatments
Number of subjects: 71
Study 22322991 — intervention group
Group type: EXPERIMENTAL
Intervention: Play-integrated preparatory programme
Number of subjects: 142
Study 22322991 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 142
Study 21549637 — intervention group
Group type: EXPERIMENTAL
Intervention: Active HF-rTMS session
Number of subjects: 20
Study 21549637 — intervention group
Group type: COMPARATOR
Intervention: Sham HF-rTMS
Number of subjects: 20
Study 18452255 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil (0.05 microg/kg/min for 2 days)
Number of subjects: 56
Study 18452255 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl (0.5 microg/kg/hr)
Number of subjects: 56
Study 17041823 — intervention group
Group type: EXPERIMENTAL
Intervention: Imitative treatment
Number of subjects: 14
Study 17041823 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-linguistic treatment
Number of subjects: 14
Study 12848585 — intervention group
Group type: EXPERIMENTAL
Intervention: BIA 3‐202 10-800mg
Number of subjects: 63
Study 12848585 — intervention group
Group type: EXPERIMENTAL
Intervention: BIA 3‐202 400mg
Number of subjects: 63
Study 12848585 — intervention group
Group type: EXPERIMENTAL
Intervention: BIA 3‐202
Number of subjects: 63
Study 12848585 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 10841825 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment with buserelin and tamoxifen
Number of subjects: 161
Study 10841825 — intervention group
Group type: COMPARATOR
Intervention: Buserelin alone
Number of subjects: 161
Study 10841825 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen alone
Number of subjects: 161
Study 9335367 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-coated cardiopulmonary bypass system
Number of subjects: 31
Study 9335367 — intervention group
Group type: COMPARATOR
Intervention: Noncoated cardiopulmonary bypass system
Number of subjects: 31
Study 9335367 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 31
Study 8076058 — intervention group
Group type: EXPERIMENTAL
Intervention: Leucocyte depletion
Number of subjects: 26
Study 8076058 — intervention group
Group type: COMPARATOR
Intervention: Control (undepleted leucocytes)
Number of subjects: 26
Study 3026017 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulbactam plus ampicillin
Number of subjects: 73
Study 3026017 — intervention group
Group type: COMPARATOR
Intervention: Metronidazole plus cefotaxime
Number of subjects: 73
Study 30103761 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose, high-frequency plus mobile mentoring (LDHF)
Number of subjects: 300
Study 30103761 — intervention group
Group type: COMPARATOR
Intervention: Traditional group-based training (TRAD)
Number of subjects: 300
Study 26763172 — intervention group
Group type: EXPERIMENTAL
Intervention: Range of motion exercises
Number of subjects: 94
Study 26763172 — intervention group
Group type: COMPARATOR
Intervention: Control (no range of motion exercises)
Number of subjects: 94
Study 24240061 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic exercise with ultrasound and microcurrent therapy
Number of subjects: 20
Study 24240061 — intervention group
Group type: COMPARATOR
Intervention: Therapeutic exercise with ultrasound alone
Number of subjects: 20
Study 24614995 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 50,000 IU weekly
Number of subjects: 64
Study 24614995 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 21191362 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein (HP) formula
Number of subjects: 601
Study 21191362 — intervention group
Group type: COMPARATOR
Intervention: Low-protein (LP) formula
Number of subjects: 601
Study 21191362 — intervention group
Group type: COMPARATOR
Intervention: Breastfed (BF) infants
Number of subjects: 601
Study 18701603 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine and Isoproterenol
Number of subjects: 100
Study 18701603 — intervention group
Group type: COMPARATOR
Intervention: Control (Group A)
Number of subjects: 100
Study 18701603 — intervention group
Group type: COMPARATOR
Intervention: Abnormal response to Atropine (Group B)
Number of subjects: 100
Study 16679823 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycerol-based hydration cream
Number of subjects: 26
Study 16679823 — intervention group
Group type: COMPARATOR
Intervention: Control (baseline values)
Number of subjects: 26
Study 14607581 — intervention group
Group type: EXPERIMENTAL
Intervention: CEE 0.625/MPA 2.5
Number of subjects: 822
Study 14607581 — intervention group
Group type: EXPERIMENTAL
Intervention: CEE 0.45/MPA 2.5
Number of subjects: 822
Study 14607581 — intervention group
Group type: EXPERIMENTAL
Intervention: CEE 0.45/MPA 1.5
Number of subjects: 822
Study 14607581 — intervention group
Group type: EXPERIMENTAL
Intervention: CEE 0.3/MPA 1.5
Number of subjects: 822
Study 14607581 — intervention group
Group type: EXPERIMENTAL
Intervention: CEE 0.3 mg
Number of subjects: 822
Study 14607581 — intervention group
Group type: EXPERIMENTAL
Intervention: CEE 0.625 mg
Number of subjects: 822
Study 14607581 — intervention group
Group type: EXPERIMENTAL
Intervention: CEE-alone groups
Number of subjects: 822
Study 14607581 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 822
Study 11068483 — intervention group
Group type: EXPERIMENTAL
Intervention: I‐T4
Number of subjects: 82
Study 11068483 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study 8817007 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulatory blood pressure (ABP) group, lisinopril 10 mg/day, could be adjusted to 10 or 20 mg/day or discontinued after one month based on blood pressure levels.
Number of subjects: 207
Study 8817007 — intervention group
Group type: COMPARATOR
Intervention: Conventional blood pressure (CBP) group, lisinopril 10 mg/day, could be adjusted to 10 or 20 mg/day or discontinued after one month based on blood pressure levels.
Number of subjects: 207
Study 8817007 — intervention group
Group type: EXPERIMENTAL
Intervention: ABP group
Number of subjects: 207
Study 8817007 — intervention group
Group type: COMPARATOR
Intervention: CBP group
Number of subjects: 207
Study 1576849 — intervention group
Group type: EXPERIMENTAL
Intervention: High work rate training (45 min/day)
Number of subjects: 19
Study 1576849 — intervention group
Group type: EXPERIMENTAL
Intervention: Low work rate training (proportionally longer time)
Number of subjects: 19
Study 1576849 — intervention group
Group type: COMPARATOR
Intervention: Comparison of high vs low work rate training
Number of subjects: 19
Study 3329079 — intervention group
Group type: EXPERIMENTAL
Intervention: Norinyl 1/35
Number of subjects: 299
Study 3329079 — intervention group
Group type: COMPARATOR
Intervention: Norinyl 1/50
Number of subjects: 299
Study 31663816 — intervention group
Group type: EXPERIMENTAL
Intervention: Anabolic androgen steroids (AS) users
Number of subjects: 181
Study 31663816 — intervention group
Group type: COMPARATOR
Intervention: Non-anabolic androgen steroids (AS) users
Number of subjects: 181
Study 29929030 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1 (≥3 mm spondylolisthesis difference between F/E radiographs)
Number of subjects: 77
Study 29929030 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2 (≥3 mm spondylolisthesis difference between U/S imaging)
Number of subjects: 77
Study 29929030 — intervention group
Group type: COMPARATOR
Intervention: Group 1 and Group 2 (comparison)
Number of subjects: 77
Study 27450744 — intervention group
Group type: EXPERIMENTAL
Intervention: Active high frequency (theta patterned) rTMS
Number of subjects: 40
Study 27450744 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 40
Study 25424122 — intervention group
Group type: EXPERIMENTAL
Intervention: Fingolimod
Number of subjects: 1053
Study 22883632 — intervention group
Group type: EXPERIMENTAL
Intervention: TF-TAVR using first-generation Edwards-Sapien valves and delivery systems via a 22- or 24-F sheath
Number of subjects: 419
Study 22883632 — intervention group
Group type: EXPERIMENTAL
Intervention: TF-TAVR
Number of subjects: 419
Study 20456103 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive hand hygiene
Number of subjects: 23
Study 20456103 — intervention group
Group type: COMPARATOR
Intervention: Control (non-wet workers)
Number of subjects: 23
Study 18639533 — intervention group
Group type: EXPERIMENTAL
Intervention: Explicit anxiety
Number of subjects: 0
Study 18639533 — intervention group
Group type: EXPERIMENTAL
Intervention: Implicit anxiety
Number of subjects: 0
Study 16647514 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric-coated mycophenolate sodium (EC‐MPS)
Number of subjects: 90
Study 16647514 — intervention group
Group type: COMPARATOR
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 90
Study 12823676 — intervention group
Group type: EXPERIMENTAL
Intervention: Empirical treatment using agents for inflammatory bowel disease
Number of subjects: 0
Study 10418645 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl (7 micrograms/kg)
Number of subjects: 60
Study 10418645 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil (1 microgram/kg)
Number of subjects: 60
Study 7767058 — intervention group
Group type: EXPERIMENTAL
Intervention: TCM-WM
Number of subjects: 62
Study 7767058 — intervention group
Group type: COMPARATOR
Intervention: WM
Number of subjects: 62
Study 1968354 — intervention group
Group type: EXPERIMENTAL
Intervention: sulphasalazine
Number of subjects: 62
Study 1968354 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 62
Study 1968354 — intervention group
Group type: EXPERIMENTAL
Intervention: sulphasalazine (subgroup with ESR > 20 mm/h)
Number of subjects: 62
Study 631039 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral doses of Ro 10-9359 (initial dose 1.0 mg/kg body-weight daily, reduced to 25-50 mg daily)
Number of subjects: 291
Study 631039 — intervention group
Group type: COMPARATOR
Intervention: Classical local dithranol application
Number of subjects: 291
Study 631039 — intervention group
Group type: EXPERIMENTAL
Intervention: Both oral Ro 10-9359 and local dithranol application
Number of subjects: 291
Study 31766250 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose iron MNP (5.0 mg iron)
Number of subjects: 327
Study 31766250 — intervention group
Group type: COMPARATOR
Intervention: Standard MNP (12.5 mg iron)
Number of subjects: 327
Study 28947039 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16590
Study 28947039 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone furoate 100 μg (FF)
Number of subjects: 16590
Study 28947039 — intervention group
Group type: COMPARATOR
Intervention: Vilanterol 25 μg (VI)
Number of subjects: 16590
Study 28947039 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone furoate 100 μg combined with vilanterol 25 μg (FF/VI)
Number of subjects: 16590
Study 26520227 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness Therapy for Maladaptive Interpersonal Dependency (MT‐MID)
Number of subjects: 48
Study 26520227 — intervention group
Group type: COMPARATOR
Intervention: Minimal contact control
Number of subjects: 48
Study 23907542 — intervention group
Group type: EXPERIMENTAL
Intervention: Orderly room
Number of subjects: 0
Study 23907542 — intervention group
Group type: COMPARATOR
Intervention: Disorderly room
Number of subjects: 0
Study 22224245 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurorehabilitation using stabilizing platforms
Number of subjects: 0
Study 22224245 — intervention group
Group type: COMPARATOR
Intervention: Computerized dynamic posturography with visual biofeedback
Number of subjects: 0
Study 19191937 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse Practitioner (NP)
Number of subjects: 1501
Study 19191937 — intervention group
Group type: COMPARATOR
Intervention: General Practitioner (GP)
Number of subjects: 1501
Study 16317312 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone (4.6 mg/day mean dose)
Number of subjects: 283
Study 16317312 — intervention group
Group type: COMPARATOR
Intervention: Placebo (previously) then Risperidone
Number of subjects: 283
Study 16317312 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 283
Study 15271001 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction task for 5-year-olds
Number of subjects: 50
Study 15271001 — intervention group
Group type: EXPERIMENTAL
Intervention: Training 5-year-olds to perform induction in an adultlike manner
Number of subjects: 50
Study 15271001 — intervention group
Group type: COMPARATOR
Intervention: Adults performing induction task
Number of subjects: 50
Study 10853624 — intervention group
Group type: EXPERIMENTAL
Intervention: β-blockers
Number of subjects: 0
Study 10853624 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-question global assessment
Number of subjects: 0
Study 9313875 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose melphalan and autograft
Number of subjects: 195
Study 9313875 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon (IFN) maintenance therapy
Number of subjects: 195
Study 9313875 — intervention group
Group type: COMPARATOR
Intervention: Melphalan or busulfan alone
Number of subjects: 195
Study 9313875 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential therapy package including IFN
Number of subjects: 195
Study 8313405 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg of nifedipine (Group II)
Number of subjects: 18
Study 8313405 — intervention group
Group type: COMPARATOR
Intervention: Solvent (Group I)
Number of subjects: 18
Study 3104433 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine 1.0 microgram X kg‐1 X min‐1
Number of subjects: 50
Study 3104433 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 0.7 microgram X kg‐1 X min‐1
Number of subjects: 50
Study 3104433 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine
Number of subjects: 50
Study 3104433 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin (TNG) 0.5 microgram X kg‐1 X min‐1
Number of subjects: 50
Study 3104433 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% NaCl)
Number of subjects: 50
Study 31718940 — intervention group
Group type: EXPERIMENTAL
Intervention: molecular quantitative trait loci (molQTLs)
Number of subjects: 0
Study 31718940 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 29406179 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 16
Study 29406179 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 29406179 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol
Number of subjects: 16
Study 27760081 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxybutynin 15 mg once daily
Number of subjects: 148
Study 27760081 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 148
Study 24068437 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic attribution for schizophrenia
Number of subjects: 149
Study 24068437 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic attribution for bipolar disorder
Number of subjects: 149
Study 24068437 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic attribution for major depression
Number of subjects: 149
Study 24068437 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic attribution for affective disorders (bipolar disorder and major depression)
Number of subjects: 149
Study 23849436 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting state (clinofibrate 400 mg)
Number of subjects: 12
Study 23849436 — intervention group
Group type: COMPARATOR
Intervention: Fed state (clinofibrate 400 mg)
Number of subjects: 12
Study 21181364 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine treatment plus simvastatin (group R+S)
Number of subjects: 40
Study 21181364 — intervention group
Group type: COMPARATOR
Intervention: Routine treatment (group R)
Number of subjects: 40
Study 21181364 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy individuals)
Number of subjects: 40
Study 17428528 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamphetamine (10mg daily for 5 days)
Number of subjects: 37
Study 17428528 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 16636633 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress-management program (lectures, coping measures, recording sheets, e-mail counseling) for 3 months
Number of subjects: 58
Study 16636633 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 58
Study 12804059 — intervention group
Group type: COMPARATOR
Intervention: 0 mA
Number of subjects: 24
Study 12804059 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mA, 0.5 mA, 1.0 mA, 2.0 mA, 3.0 mA for 20 min
Number of subjects: 24
Study 12804059 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mA for 40 min
Number of subjects: 24
Study 12804059 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.0 mA for 20 min
Number of subjects: 24
Study 10343626 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled Fluticasone Propionate (FP) 880 micrograms bid + Intranasal Fluticasone Propionate (FP) 200 micrograms once daily
Number of subjects: 12
Study 10343626 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled Triamcinolone Acetonide (TAA) 880 micrograms bid + Intranasal Triamcinolone Acetonide (TAA) 220 micrograms once daily
Number of subjects: 12
Study 10343626 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled Fluticasone Propionate (FP)
Number of subjects: 12
Study 10343626 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled Triamcinolone Acetonide (TAA)
Number of subjects: 12
Study 10343626 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal Fluticasone Propionate (FP)
Number of subjects: 12
Study 10343626 — intervention group
Group type: COMPARATOR
Intervention: Placebo (nPL + inhPL)
Number of subjects: 12
Study 8606898 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurodevelopmental treatment (NDT) for 5 days
Number of subjects: 8
Study 8606898 — intervention group
Group type: EXPERIMENTAL
Intervention: Practice of reaching tasks for 5 days
Number of subjects: 8
Study 8606898 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments combined
Number of subjects: 8
Study 8606898 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment duration (both types)
Number of subjects: 8
Study 1945978 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen A (chloral hydrate 50 mg/kg + hydroxyzine pamoate 25 mg + meperidine 1.5 mg/kg)
Number of subjects: 10
Study 1945978 — intervention group
Group type: COMPARATOR
Intervention: Regimen B (chloral hydrate 50 mg/kg + hydroxyzine pamoate 25 mg)
Number of subjects: 10
Study 7047580 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine (0.3, 0.45, or 0.6 mg)
Number of subjects: 97
Study 7047580 — intervention group
Group type: COMPARATOR
Intervention: Morphine (10, 15, or 20 mg)
Number of subjects: 97
Study 30446577 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-star GRIP rated slip resistant footwear
Number of subjects: 4400
Study 30446577 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group (no footwear during trial)
Number of subjects: 4400
Study 26547513 — intervention group
Group type: EXPERIMENTAL
Intervention: Vortex Blue (VB)
Number of subjects: 60
Study 26547513 — intervention group
Group type: EXPERIMENTAL
Intervention: ProTaper Next (PTN)
Number of subjects: 60
Study 26547513 — intervention group
Group type: COMPARATOR
Intervention: K3XF
Number of subjects: 60
Study 26547513 — intervention group
Group type: COMPARATOR
Intervention: Reciproc
Number of subjects: 60
Study 25242220 — intervention group
Group type: EXPERIMENTAL
Intervention: Spatial attention
Number of subjects: 0
Study 25242220 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention field and pRF without attention
Number of subjects: 0
Study 22221140 — intervention group
Group type: EXPERIMENTAL
Intervention: AV608 (NK1R antagonist)
Number of subjects: 11
Study 22221140 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 20137767 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol Contramid OAD 200 mg tablets
Number of subjects: 30
Study 20137767 — intervention group
Group type: COMPARATOR
Intervention: Monocrixo L.P. 200 mg capsules
Number of subjects: 30
Study 17700548 — intervention group
Group type: EXPERIMENTAL
Intervention: GRAIDS (Genetic Risk Assessment on the Internet with Decision Support) support
Number of subjects: 45
Study 17700548 — intervention group
Group type: COMPARATOR
Intervention: Comparison (education and mailed guidelines)
Number of subjects: 45
Study 16199694 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen delivery through nasal cannulae with effective FIO2 <0.23
Number of subjects: 187
Study 16199694 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen delivery through nasal cannulae with effective FIO2 of 0.21
Number of subjects: 187
Study 16199694 — intervention group
Group type: EXPERIMENTAL
Intervention: Room air through nasal cannulae
Number of subjects: 187
Study 16199694 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen delivery with effective FIO2 <0.23
Number of subjects: 187
Study 12243129 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced lifestyle interventions (EI)
Number of subjects: 1586
Study 12243129 — intervention group
Group type: COMPARATOR
Intervention: Minimum intervention (MI)
Number of subjects: 1586
Study 9990416 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapalene 0.1% gel
Number of subjects: 100
Study 9990416 — intervention group
Group type: COMPARATOR
Intervention: Tretinoin 0.025% cream
Number of subjects: 100
Study 8295245 — intervention group
Group type: EXPERIMENTAL
Intervention: Clotrimazole 10 mg three times a day
Number of subjects: 292
Study 8295245 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole 200 mg per day
Number of subjects: 292